vs
Side-by-side financial comparison of CHAMPIONS ONCOLOGY, INC. (CSBR) and SOLESENCE, INC. (SLSN). Click either name above to swap in a different company.
CHAMPIONS ONCOLOGY, INC. is the larger business by last-quarter revenue ($15.0M vs $12.5M, roughly 1.2× SOLESENCE, INC.). CHAMPIONS ONCOLOGY, INC. runs the higher net margin — 1.8% vs 1.3%, a 0.5% gap on every dollar of revenue. On growth, CHAMPIONS ONCOLOGY, INC. posted the faster year-over-year revenue change (11.5% vs -0.7%). Over the past eight quarters, SOLESENCE, INC.'s revenue compounded faster (12.5% CAGR vs 11.8%).
Champions Oncology is an American technology company that develops mouse avatars. Called TumorGrafts, they are used to test a panel of chemotherapy regimens, targeted therapies and monoclonal antibodies to identify potential therapeutic options for cancer patients. The company was founded in 2007 by David Sidransky, M.D., a Johns Hopkins University oncologist.
CSBR vs SLSN — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $15.0M | $12.5M |
| Net Profit | $268.0K | $163.0K |
| Gross Margin | 51.7% | 27.5% |
| Operating Margin | 1.2% | 1.5% |
| Net Margin | 1.8% | 1.3% |
| Revenue YoY | 11.5% | -0.7% |
| Net Profit YoY | -63.2% | 129.2% |
| EPS (diluted) | $0.02 | $0.00 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $15.0M | $12.5M | ||
| Q3 25 | $14.0M | $14.6M | ||
| Q2 25 | $12.4M | $20.4M | ||
| Q1 25 | $17.0M | $14.6M | ||
| Q4 24 | $13.5M | $12.6M | ||
| Q3 24 | $14.1M | $16.9M | ||
| Q2 24 | $14.0M | $13.0M | ||
| Q1 24 | $12.0M | $9.9M |
| Q4 25 | $268.0K | $163.0K | ||
| Q3 25 | $-436.0K | $-1.1M | ||
| Q2 25 | $-1.8M | $2.7M | ||
| Q1 25 | $4.5M | $80.0K | ||
| Q4 24 | $728.0K | $-559.0K | ||
| Q3 24 | $1.3M | $3.0M | ||
| Q2 24 | $-109.0K | $856.0K | ||
| Q1 24 | $-2.5M | $893.0K |
| Q4 25 | 51.7% | 27.5% | ||
| Q3 25 | 42.9% | 23.1% | ||
| Q2 25 | 41.1% | 28.9% | ||
| Q1 25 | 61.2% | 23.1% | ||
| Q4 24 | 44.9% | 22.0% | ||
| Q3 24 | 49.7% | 36.2% | ||
| Q2 24 | 48.2% | 28.7% | ||
| Q1 24 | 34.7% | 36.3% |
| Q4 25 | 1.2% | 1.5% | ||
| Q3 25 | -3.8% | -5.4% | ||
| Q2 25 | -16.2% | 9.4% | ||
| Q1 25 | 26.4% | 1.8% | ||
| Q4 24 | 5.4% | -1.8% | ||
| Q3 24 | 9.5% | 19.0% | ||
| Q2 24 | -1.9% | 8.0% | ||
| Q1 24 | -21.4% | 11.3% |
| Q4 25 | 1.8% | 1.3% | ||
| Q3 25 | -3.1% | -7.7% | ||
| Q2 25 | -14.9% | 13.1% | ||
| Q1 25 | 26.4% | 0.5% | ||
| Q4 24 | 5.4% | -4.4% | ||
| Q3 24 | 9.3% | 18.1% | ||
| Q2 24 | -0.8% | 6.6% | ||
| Q1 24 | -21.1% | 9.0% |
| Q4 25 | $0.02 | $0.00 | ||
| Q3 25 | $-0.03 | $-0.02 | ||
| Q2 25 | $-0.12 | $0.04 | ||
| Q1 25 | $0.31 | $0.00 | ||
| Q4 24 | $0.05 | $0.00 | ||
| Q3 24 | $0.09 | $0.04 | ||
| Q2 24 | $-0.01 | $0.01 | ||
| Q1 24 | $-0.19 | $0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.5M | $1.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $4.2M | $17.6M |
| Total Assets | $30.2M | $50.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.5M | $1.3M | ||
| Q3 25 | $10.3M | $429.0K | ||
| Q2 25 | $9.8M | $4.1M | ||
| Q1 25 | $3.2M | $1.8M | ||
| Q4 24 | $2.8M | $1.4M | ||
| Q3 24 | $2.9M | $2.9M | ||
| Q2 24 | $2.6M | $2.4M | ||
| Q1 24 | $4.5M | $2.0M |
| Q4 25 | $4.2M | $17.6M | ||
| Q3 25 | $3.5M | $17.2M | ||
| Q2 25 | $3.8M | $18.2M | ||
| Q1 25 | $5.5M | $15.2M | ||
| Q4 24 | $681.0K | $14.9M | ||
| Q3 24 | $-332.0K | $15.2M | ||
| Q2 24 | $-1.9M | $11.9M | ||
| Q1 24 | $-2.1M | $5.0M |
| Q4 25 | $30.2M | $50.1M | ||
| Q3 25 | $30.5M | $54.0M | ||
| Q2 25 | $32.3M | $60.0M | ||
| Q1 25 | $30.6M | $57.0M | ||
| Q4 24 | $25.2M | $50.0M | ||
| Q3 24 | $24.9M | $48.0M | ||
| Q2 24 | $26.1M | $40.8M | ||
| Q1 24 | $26.8M | $38.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.7M | $1.8M |
| Free Cash FlowOCF − Capex | $-2.0M | — |
| FCF MarginFCF / Revenue | -13.1% | — |
| Capex IntensityCapex / Revenue | 1.6% | — |
| Cash ConversionOCF / Net Profit | -6.47× | 11.16× |
| TTM Free Cash FlowTrailing 4 quarters | $5.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.7M | $1.8M | ||
| Q3 25 | $600.0K | $-2.5M | ||
| Q2 25 | $6.9M | $-654.0K | ||
| Q1 25 | $490.0K | $-7.2M | ||
| Q4 24 | $-283.0K | $2.2M | ||
| Q3 24 | $311.0K | $4.2M | ||
| Q2 24 | $-1.8M | $-565.0K | ||
| Q1 24 | $-919.0K | $-3.9M |
| Q4 25 | $-2.0M | — | ||
| Q3 25 | $554.0K | — | ||
| Q2 25 | $6.6M | — | ||
| Q1 25 | $448.0K | — | ||
| Q4 24 | $-377.0K | $-404.0K | ||
| Q3 24 | — | $2.8M | ||
| Q2 24 | $-1.8M | $-1.0M | ||
| Q1 24 | $-1.0M | $-3.9M |
| Q4 25 | -13.1% | — | ||
| Q3 25 | 4.0% | — | ||
| Q2 25 | 53.5% | — | ||
| Q1 25 | 2.6% | — | ||
| Q4 24 | -2.8% | -3.2% | ||
| Q3 24 | — | 16.6% | ||
| Q2 24 | -13.0% | -8.0% | ||
| Q1 24 | -8.4% | -39.9% |
| Q4 25 | 1.6% | — | ||
| Q3 25 | 0.3% | — | ||
| Q2 25 | 2.0% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 0.7% | 20.6% | ||
| Q3 24 | 0.0% | 8.3% | ||
| Q2 24 | 0.0% | 3.7% | ||
| Q1 24 | 0.8% | 0.9% |
| Q4 25 | -6.47× | 11.16× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -0.25× | ||
| Q1 25 | 0.11× | -90.26× | ||
| Q4 24 | -0.39× | — | ||
| Q3 24 | 0.24× | 1.38× | ||
| Q2 24 | — | -0.66× | ||
| Q1 24 | — | -4.32× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CSBR
| Pharmacology Services | $14.5M | 97% |
| Other | $520.0K | 3% |
SLSN
Segment breakdown not available.
